Research analysts at Canaccord Genuity Group started coverage on shares of Stoke Therapeutics (NASDAQ:STOK – Get Rating) in a research note issued to investors on Wednesday, FinViz reports. The brokerage set a “buy” rating and a $24.00 price target on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 169.06% from the […]
Should You Buy or Sell Stoke Therapeutics Stock? Get The Latest STOK Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Stoke Therapeutics (NASDAQ:STOK – Get Rating) and CytomX Therapeutics (NASDAQ:CTMX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Analyst Recommendations This is a breakdown of recent ratings […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month […]
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) have earned an average rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price target among […]